Enfortumab vedotin
Enfortumab vedotin (pronunciation: en-for-TOO-mab ve-DOE-tin) is a type of antibody-drug conjugate used in the treatment of certain types of cancer, specifically urothelial carcinoma.
Etymology
The name "Enfortumab vedotin" is derived from its components. "Enfortumab" refers to the monoclonal antibody that targets the protein nectin-4, which is overexpressed in urothelial carcinoma. "Vedotin" refers to the chemotherapeutic agent that is conjugated to the antibody, which is released into the cancer cell upon binding.
Usage
Enfortumab vedotin is used for the treatment of locally advanced or metastatic urothelial carcinoma that has previously been treated with a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy.
Mechanism of Action
Enfortumab vedotin works by binding to the nectin-4 protein on the surface of cancer cells. Upon binding, the drug is internalized into the cell where the vedotin component is released. This chemotherapeutic agent then interferes with the cell's ability to divide and grow, leading to cell death.
Side Effects
Common side effects of enfortumab vedotin include fatigue, peripheral neuropathy, decreased appetite, rash, and nausea. More serious side effects can include hyperglycemia, pneumonitis, and peripheral neuropathy.
Related Terms
- Antibody-drug conjugate
- Monoclonal antibody
- Nectin-4
- Urothelial carcinoma
- PD-1
- PD-L1
- Platinum-containing chemotherapy
External links
- Medical encyclopedia article on Enfortumab vedotin
- Wikipedia's article - Enfortumab vedotin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski